View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
This trial is available at multiple Sutter Locations. Please contact one of the following about Study SWOG S2001
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky firstname.lastname@example.org
PAMF/Fremont: Tanya Pozniansky email@example.com
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Modesto: Stephanie Edmondson firstname.lastname@example.org
Solano-Vallejo Cancer Center: Stephanie Gonzales email@example.com
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org